文献速递胸部肿瘤消化系统肿瘤骨软组织肉瘤与黑色素瘤

Mosperafenib(新型矛盾打破型BRAF抑制剂)在BRAF V600突变实体瘤中的I期研究

Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors.
PubMed 文献 · J Clin Oncol · 2026-03-27

这项Ia/b期研究评估了新型矛盾打破型、可入脑的BRAF抑制剂Mosperafenib在BRAF V600突变晚期实体瘤患者中的安全性、最大耐受剂量、药代动力学和初步临床活性。80例患者(60%曾暴露于BRAF抑制剂)接受单药治疗,未达到最大耐受剂量,3-4级治疗相关不良事件发生率为16.3%,总体缓解率为24.2%。

要点

  • Mosperafenib在BRAF V600突变实体瘤中安全性良好,未达到最大耐受剂量。
  • 总体缓解率为24.2%,包括2例完全缓解和14例部分缓解。
  • 结直肠癌患者中位无进展生存期为6.4个月,黑色素瘤患者为3.5个月。

核心结论

  • Mosperafenib展现出良好的安全性、持续的目标抑制以及在BRAF抑制剂初治和经治患者中具有临床意义的单药活性的早期迹象。

研究设计与样本

  • 这是一项Ia/b期研究,纳入携带BRAF V600突变的晚期实体瘤患者(ISRCTN13713551)。
  • 采用改良连续重评估方法指导剂量递增,Mosperafenib口服给药,最高至3600 mg每日一次,28天为一周期。
  • 主要目标是估计最大耐受剂量和/或推荐II期剂量。
  • 共80例患者接受至少一剂Mosperafenib单药治疗,其中60%曾暴露于BRAF抑制剂;63例为结直肠癌,13例为黑色素瘤,4例为其他实体瘤。
  • 治疗中位持续时间为3.7个月(范围0.2-28.6)。

主要发现

  • 报告了2例剂量限制性3级毒性:皮疹和斑丘疹。
  • 未达到最大耐受剂量。
  • 13例患者(16.3%)发生3-4级治疗相关不良事件;未报告5级治疗相关不良事件。
  • 2例患者(2.5%)因治疗相关不良事件终止研究治疗。
  • 未报告掌跖红斑感觉异常综合征或角化棘皮瘤。

关键数值与推荐

  • 剂量限制性毒性:2例3级皮疹和斑丘疹。
  • 最大耐受剂量未达到。
  • 3-4级治疗相关不良事件发生率:16.3%(13/80)。
  • 因治疗相关不良事件终止治疗:2.5%(2/80)。
  • 总体缓解率:24.2%,含2例完全缓解和14例部分缓解。

临床怎么用

  • Mosperafenib在BRAF V600突变实体瘤中显示出可管理的安全性和初步抗肿瘤活性,支持进一步临床开发。
  • 未达到最大耐受剂量,需在后续研究中确定推荐II期剂量。
  • 药代动力学显示持续pERK抑制≥90%,支持每日给药方案的探索。

局限性

  • 样本量有限(80例),且为非随机单臂研究。
  • 患者群体异质,包括不同瘤种和既往BRAF抑制剂暴露状态。
  • 未达到最大耐受剂量,推荐II期剂量尚未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: BRAF V600 mutations are tumor-agnostic oncogenic drivers whose targeted inhibition is challenged by therapeutic resistance. Mosperafenib is a novel paradox breaker and brain-penetrant BRAF inhibitor (BRAFi), tested in this study for safety, maximum tolerated dose (MTD), pharmacokinetics (PK), and preliminary clinical activity. PATIENTS AND METHODS: This phase Ia/b study was conducted in patients with advanced solid tumors harboring a BRAF V600 mutation (ISRCTN13713551). The modified continuous reassessment method guided dose escalation of mosperafenib, which was given orally up to 3,600 mg once daily in 28-day cycles. The primary objective was to estimate the MTD and/or recommended phase II dose(s). RESULTS: Eighty patients (60% BRAFi-exposed)-63 with colorectal cancer (CRC), 13 with melanoma, and 4 with other solid tumors-received ≥1 dose of mosperafenib as a single agent for a median of 3.7 months (range, 0.2-28.6). Two dose-limiting grade 3 toxicities of rash and rash maculopapular were reported. MTD was not reached. Grade 3 to 4 treatment-related adverse events (TRAEs) occurred in 13 patients (16.3%); no grade 5 TRAEs events were reported. Two patients (2.5%) discontinued study treatment due to TRAEs. There were no reports of palmar-plantar erythrodysesthesia or keratoacanthoma. Linear and time-independent PK was demonstrated across the tested dose range, achieving exposure levels with sustained PK-derived pERK inhibition ≥90%. An exposure-response relationship was observed. Overall response rate was 24.2%, including two complete responses and 14 partial responses. Median progression-free survival was 6.4 months in patients with CRC (200 mg once daily-1200 mg three times a day) and 3.5 months in patients with melanoma (200 mg once daily-800 mg twice a day). CONCLUSION: Mosperafenib demonstrated a favorable safety profile, sustained target inhibition, and early signs of clinically meaningful single-agent activity in BRAFi-naïve and BRAFi-exposed patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Vieito M, Fontana E, Han CH, et al. Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors. J Clin Oncol. 2026. PMID: 41894647. doi:10.1200/JCO-25-02444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。